MRI-guided Focal laser ablation (FLA) is used to treat prostate cancer. Contrast enhanced imaging can assess the ablated region, but cannot be used during ablation due to effects of high energy ultrasound on MRI contrast agent stability. Our results show that high resolution MR spectroscopic imaging of the water resonance detects changes in T2* and water resonance peak amplitude that clearly delineate the ablation zone without contrast agent injection. Ablation zones measured by MR spectroscopic imaging are consistent with contrast enhanced images. This suggests that MR spectroscopic imaging can guide FLA during ablation to dynamically optimize treatment and improve outcomes.